泰林生物(300813.SZ)將於1月14日上市 預計2019年度淨利潤微增2.91%
格隆匯1月12日丨泰林生物(300813.SZ)發佈首次公開發行股票並在創業板上市之上市公告書,公開發行1300萬股,全部為新股發行,不涉及老股轉讓;發行價為18.35元/股;將於1月14日在深圳證券交易所創業板上市。
公司根據目前在手訂單、產品庫存及生產計劃等,初步預計2019年度營業收入1.92億元,同比增長20.66%。歸屬於公司股東的淨利潤為4962萬元,同比增長2.91%。扣除非經常性損益後歸屬於母公司股東的淨利潤4292萬元,同比增長3.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.